Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13
Artelo Biosciences received a patent allowance decision from the Japanese Patent Office for ART27.13, a peripherally selective dual cannabinoid agonist in Phase 2 trials for cancer-related anorexia and glaucoma. This notification completes patent allowance for ART27.13 in the US, Europe, and Japan, securing intellectual property protection through …